|
|
Volumn 68, Issue 10, 2010, Pages 876-878
|
|
What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALZHEIMER DISEASE VACCINE;
AMYLOID BETA PROTEIN;
AMYLOID BETA PROTEIN[1-42];
AMYLOID PRECURSOR PROTEIN;
ATORVASTATIN;
BAPINEUZUMAB;
BETA SECRETASE;
CYANOCOBALAMIN;
DIMEBON;
DOCOSAHEXAENOIC ACID;
ESTROGEN;
FOLIC ACID;
GAMMA SECRETASE;
HOMOTAURINE;
LEUPRORELIN;
NAPROXEN;
PHENSERINE;
PLACEBO;
PREDNISONE;
PYRIDOXINE;
ROFECOXIB;
ROSIGLITAZONE;
SEMAGACESTAT;
TARENFLURBIL;
VALPROIC ACID;
XALIPRODEN;
ALZHEIMER DISEASE;
DISEASE SEVERITY;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG SAFETY;
DRUG TREATMENT FAILURE;
DRUG WITHDRAWAL;
HEALTH CARE COST;
HUMAN;
NONHUMAN;
NOTE;
OUTCOME ASSESSMENT;
PATHOPHYSIOLOGY;
PRIORITY JOURNAL;
PROTEIN FUNCTION;
SKIN CANCER;
ALANINE;
ALZHEIMER DISEASE;
AMYLOID;
AMYLOID PRECURSOR PROTEIN SECRETASES;
AZEPINES;
COGNITION DISORDERS;
EARLY TERMINATION OF CLINICAL TRIALS;
HUMANS;
MULTICENTER STUDIES AS TOPIC;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
SKIN NEOPLASMS;
TREATMENT FAILURE;
|
|
EID: 78049423315
PISSN: 00063223
EISSN: None
Source Type: Journal
DOI: 10.1016/j.biopsych.2010.09.020 Document Type: Note |
|
Times cited : (57)
|
|
References (9)
|
